Literature DB >> 32303505

Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear.

Ingrid Torjesen1.   

Abstract

Entities:  

Year:  2020        PMID： 32303505     DOI： 10.1136/bmj.m1555

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  9 in total

Review 1.  COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

Authors:  Dâmaris Silveira; Jose Maria Prieto-Garcia; Fabio Boylan; Omar Estrada; Yris Maria Fonseca-Bazzo; Claudia Masrouah Jamal; Pérola Oliveira Magalhães; Edson Oliveira Pereira; Michal Tomczyk; Michael Heinrich
Journal:  Front Pharmacol       Date:  2020-09-23       Impact factor: 5.810

Review 2.  Safety perspectives on presently considered drugs for the treatment of COVID-19.

Authors:  Sophie L Penman; Robyn T Kiy; Rebecca L Jensen; Christopher Beoku-Betts; Ana Alfirevic; David Back; Saye H Khoo; Andrew Owen; Munir Pirmohamed; B Kevin Park; Xiaoli Meng; Christopher E Goldring; Amy E Chadwick
Journal:  Br J Pharmacol       Date:  2020-08-13       Impact factor: 8.739

3.  Does Ibuprofen Worsen COVID-19?

Authors:  Nicholas Moore; Bruce Carleton; Patrick Blin; Pauline Bosco-Levy; Cecile Droz
Journal:  Drug Saf       Date:  2020-07       Impact factor: 5.606

4.  DrugWAS: Leveraging drug-wide association studies to facilitate drug repurposing for COVID-19.

Authors:  Cosmin A Bejan; Katherine N Cahill; Patrick J Staso; Leen Choi; Josh F Peterson; Elizabeth Jane Phillips
Journal:  medRxiv       Date:  2021-02-08

5.  Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.

Authors:  Thomas M Drake; Cameron J Fairfield; Riinu Pius; Stephen R Knight; Lisa Norman; Michelle Girvan; Hayley E Hardwick; Annemarie B Docherty; Ryan S Thwaites; Peter J M Openshaw; J Kenneth Baillie; Ewen M Harrison; Malcolm G Semple
Journal:  Lancet Rheumatol       Date:  2021-05-07

Review 6.  Chronic Liver Disease and COVID-19: Alcohol Use Disorder/Alcohol-Associated Liver Disease, Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Autoimmune Liver Disease, and Compensated Cirrhosis.

Authors:  Tatyana Kushner; John Cafardi
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-05-21

Review 7.  Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic.

Authors:  Mi Ryoung Seo; Ji-Won Kim; Eun-Jung Park; Seung Min Jung; Yoon-Kyoung Sung; Hyungjin Kim; Gunwoo Kim; Hyun-Sook Kim; Myeung-Su Lee; Jisoo Lee; Ji An Hur; Bum Sik Chin; Joong Sik Eom; Han Joo Baek
Journal:  Korean J Intern Med       Date:  2020-09-15       Impact factor: 2.884

Review 8.  Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know?

Authors:  Anna Licata; Maria Giovanna Minissale; Marco Distefano; Giuseppe Montalto
Journal:  GastroHep       Date:  2021-05-03

9.  NSAIDs and COVID-19: A Systematic Review and Meta-analysis.

Authors:  Nicholas Moore; Pauline Bosco-Levy; Nicolas Thurin; Patrick Blin; Cécile Droz-Perroteau
Journal:  Drug Saf       Date:  2021-08-02       Impact factor: 5.606
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.